Trial Profile
Reduced survival in hepatocellular carcinoma (HCC) patients due to sarcopenia: A retrospective study in patients receiving sorafenib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Aug 2015
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 11 Aug 2015 New trial record